CME Group Inc.

CME
Financial Analysis · Updated May 12, 2026 · Coverage 2026-Q2
TTM ROIC
20.5%
FY2025 · NOPAT / Invested Capital (excluding clearing fund assets; including goodwill + intangibles; NOPAT ≈ Adjusted Net Income) · WACC ~8.5% · Moat spread +12pp

Financial Snapshot


ticker: CME step: 04 generated: 2026-05-12 source: quick-research

CME Group Inc. (CME) — Financial Snapshot

Income Statement Summary

Metric FY2023 FY2024 FY2025 YoY (FY25)
Revenue $5.58B $6.13B $6.51B +6.3%
Clearing & Transaction Fees $4.6B $5.1B $5.4B +6%
Market Data Revenue $0.74B $0.78B $0.83B +6%
Adjusted Operating Margin 63% 64% 65%+ +100 bps
GAAP Operating Margin ~60% ~63% ~63% flat
Adjusted Net Income $3.34B $3.67B $4.02B +9.7%
Adjusted Diluted EPS $9.24 $10.13 $11.06 +9.2%

Volume Metrics

Metric FY2024 FY2025 Trends
Annual ADV (millions of contracts) 26.9 record Q2 2025 record at 30.2M (+16%)
Interest Rate ADV record record all-time records 3 consecutive years
Equity Index ADV strong record volatility-driven
Commodity ADV strong +15% sector growth broad-based

Cash Flow & Capital Allocation (FY2025)

Metric Value
Operating Cash Flow ~$4.5B
Capital Expenditures ~$70M (asset-light)
Free Cash Flow ~$4.4B
Total Capital Returned in 2025 (incl. variable div + buybacks) ~$4.0B
2025 Annual Variable Dividend (declared Feb 2026) $6.15/share (~$2.2B)
Q1 2026 Regular Dividend $1.30 (quarterly)
Annual Regular Dividend $5.20
Total Annual Dividend Yield (regular + variable) ~4.2%
Q4 2025 Buyback $256M
YTD 2026 Buyback $276M+ (using OSTTRA proceeds)
Buyback Authorization $3B opportunistic

FY2026 Guidance

Metric 2026 Guide
Adjusted Operating Expenses (ex-license fees) ~$1.695B
Capital Expenditures ~$85M
Tax Rate 23.5–24.5%
Pricing/Fee Changes +1.0–1.5% expected revenue impact
Major Initiative CME-FICC client cross-margining launched April 30, 2026; CME Securities Clearing for Treasury cash

Key Ratios (approximate)

  • P/E: ~24x (FY26 adjusted EPS ~$11.50) | EV/EBITDA: ~18x | FCF Yield: ~4.6%
  • Revenue Growth (FY25): +6.3% | FCF Margin: ~68%
  • Adjusted Operating Margin: 65%+ (industry-best)
  • Total Capital Return Yield: ~4.2% (regular $5.20 + variable $6.15 = ~$11.35 annual)
  • ROIC: 60%+ (asset-light + clearing fund structure)

Growth Profile

FY25 was a record year:

  • Revenue +6.3% to $6.51B
  • Adjusted EPS +9.2% to $11.06
  • Net Income +15.5% to $4.02B
  • Q2 2025 ADV record 30.2M contracts (+16%)
  • All six asset classes hitting volume records

The structural story is financial-risk infrastructure monopoly:

  • Interest rate futures volumes structurally rising with debt cycles + Fed activity
  • CME-FICC cross-margining (April 30, 2026 launch) saves customers ~$80B daily margin — defends Treasury futures dominance against any potential FICC competition
  • CME Securities Clearing (Treasury cash) entry leverages clearing-network effects into adjacent market

FY26 setup: continued mid-single-digit revenue growth + operating leverage + variable dividend program supports ~5%+ total capital return yield + multiple expansion as recurring revenue mix grows.

Forward Estimates

FY2026 (Consensus):

  • Revenue: ~$6.9–7.0B (+6%)
  • Adjusted EPS: ~$11.50–12.00 (+4–8%)

Bull case: Volumes accelerate further on continued rate volatility + Treasury debt issuance + equity flows; multiple expands to 28x P/E. Bear case: 2026 rates cycle normalizes + interest rate hedging volume declines; multiple compresses to 20x P/E. Consensus targets ~$285–315 vs. trading ~$255–275 (~10–25% implied upside).

Deeper Financial Analysis

The fundamental tier adds 9 additional research dimensions for $CME.

Revenue Breakdown
Segment revenue, geographic mix, product-line contribution margins, and cohort dynamics.
Financial Trends
Quarter-over-quarter momentum, leading indicators, and inflection point analysis.
Balance Sheet
Debt structure, liquidity runway, dilution risk, and working capital dynamics.
Capital Allocation
Buyback cadence, M&A appetite, dividend policy, and reinvestment priorities.
Returns on Capital (ROIC)
Multi-year ROIC vs. WACC, marginal returns on reinvestment, sales-to-invested-capital efficiency, and moat spread.
GET /api/v1/research/CME/fundamental$1.00 · Bearer token required
Markdown: /stocks/cme/financials/md · → thesis · → memo